Viatris Sells Biocon Stake for $815 Million, Accelerates Market Access
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Source: Newsfilter
- Significant Transaction Value: Viatris has entered into agreements with Biocon to sell its equity stake in Biocon Biologics for a total consideration of $815 million, comprising $400 million in cash and $415 million in newly issued Biocon shares, reflecting the company's proactive approach to capital management.
- Accelerated Market Access: This transaction not only allows Viatris to regain access to the global biosimilars market but also accelerates the expiration of non-compete restrictions imposed in 2022, which is expected to provide significant additional optionality for future growth.
- Lock-Up Period Impact: The newly issued Biocon shares will be listed on the National Stock Exchange of India and are subject to a six-month lock-up period, which may affect Viatris' short-term liquidity but is anticipated to enhance its market position in the long run.
- Advisory Support: Citi is acting as the financial advisor to Viatris in this transaction, indicating the company's reliance on professional advisory support for strategic decisions to ensure the smooth execution and maximization of benefits from the deal.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 13.25 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 13.240
Low
10.00
Averages
13.25
High
16.00
Current: 13.240
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
